Scheduled Maintenance Notice

Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.

Select Publications

Journal articles

Frew JW; Nguyen RTD, 2015, 'Tattoo-associated mycobacterial infections: an emerging public health issue', Medical Journal of Australia, 203, pp. 223 - 223e.1, http://dx.doi.org/10.5694/MJA15.00098

Frew JW; Parsi K, 2015, 'Adalimumab-induced porokeratosis', Australasian Journal of Dermatology, 56, pp. e80 - e81, http://dx.doi.org/10.1111/ajd.12215

Frew JW; Vekic DA; Woods J; Cains GD, 2015, 'Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa', Experimental Dermatology, 24, pp. 338 - 339, http://dx.doi.org/10.1111/exd.12648

Frew JW, 2015, 'Multinucleate cell angiohistiocytoma: Clinicopathological correlation of 142 cases with insights into etiology and pathogenesis', American Journal of Dermatopathology, 37, pp. 222 - 228, http://dx.doi.org/10.1097/DAD.0000000000000075

Frew JW; Parsi K, 2014, 'Adalimumab-induced porokeratosis', AUSTRALASIAN JOURNAL OF DERMATOLOGY, 55, pp. 35 - 35, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335981400114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yuen WY; Frew JW; Veerman K; van den Heuvel ER; Murrell DF; Jonkman MF, 2014, 'Health-related quality of life in epidermolysis bullosa: Validation of the dutch QOLEB questionnaire and assessment in the dutch population', Acta Dermato Venereologica, 94, pp. 442 - 447, http://dx.doi.org/10.2340/00015555-1758

Frew JW, 2014, 'The clinical significance of drug interactions between dermatological and psychoactive medications', Dermatologic Therapy, 27, pp. 1 - 11, http://dx.doi.org/10.1111/dth.12003

Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF, 2013, 'The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease', British Journal of Dermatology, 169, pp. 1000 - 1006, http://dx.doi.org/10.1111/bjd.12623

Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JCK; Wang CQ; Welsh B; Nijsten T; Murrell DF, 2013, 'Development of a quality-of-life instrument for autoimmune bullous disease: The autoimmune bullous disease quality of life questionnaire', JAMA Dermatology, 149, pp. 1186 - 1191, http://dx.doi.org/10.1001/jamadermatol.2013.4972

Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF, 2013, 'A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa', Journal of the American Academy of Dermatology, 69, pp. 898 - 8e7, http://dx.doi.org/10.1016/j.jaad.2013.08.014

Frew JW; Cepeda Valdes R; Fortuna G; Murrell DF; Salas Alanis J, 2013, 'Measuring quality of life in epidermolysis bullosa in Mexico: Cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire', Journal of the American Academy of Dermatology, 69, pp. 652 - 653, http://dx.doi.org/10.1016/j.jaad.2013.04.053

Frew JW; Cepeda-Valdes R; Fortuna G; Salas-Alanis JC; Murrell DF, 2013, 'Cross cultural adaptation of the 'Quality of Life in Epidermolysis Bullosa' (QOLEB) questionnaire: Validation and results of a Hispanic translation', AUSTRALASIAN JOURNAL OF DERMATOLOGY, 54, pp. 39 - 40

Sebaratnam DF; Venugopal SS; Frew JW; McMillan JR; Finkelstein ER; Martin LK; Murrell DF, 2013, 'Diffuse melanosis cutis: a systematic review of the literature.', J Am Acad Dermatol, 68, pp. 482 - 488, http://dx.doi.org/10.1016/j.jaad.2012.08.018

Nyholm T; Jonsson J; Söderström K; Bergström P; Carlberg A; Frykholm G; Behrens CF; Geertsen PF; Trepiakas R; Hanvey S; Sadozye A; Ansari J; McCallum H; Frew J; McMenemin R; Zackrisson B, 2013, 'Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study', Radiation Oncology, 8, pp. 126, http://dx.doi.org/10.1186/1748-717x-8-126

Venugopal S; Yan W; Frew JW; Cohn HI; Tran K; Sturm M; Marinkovich P; Igawa S; Ishida-Yamamoto A; Murrell DF, 2012, 'INVESTIGATION OF CELL THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) THROUGH INTRADERMAL INJECTION OF ALLOGENEIC FIBROBLASTS RANDOMIZED AGAINST PLACEBO INJECTIONS OF SUSPENSION SOLUTION', WOUND REPAIR AND REGENERATION, 20, pp. A68 - A68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308945000061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sebaratnam DF; Hanna A; Chee S; Frew JW; Tan JCK; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF, 2012, 'VALIDATION OF THE PSYCHOMETRIC PROPERTIES OF A QUALITY-OF-LIFE MEASURE SPECIFIC TO AUTOIMMUNE BULLOUS DISEASE', WOUND REPAIR AND REGENERATION, 20, pp. A65 - A65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308945000051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Frew JW; Murrell DF, 2012, 'Corticosteroid Use in Autoimmune Blistering Diseases', Immunology and Allergy Clinics of North America, 32, pp. 283 - 294, http://dx.doi.org/10.1016/j.iac.2012.04.008

Sebaratnam DF; Frew JW; Davatchi F; Murrell DF, 2012, 'Quality-of-life measurement in blistering diseases.', Dermatol Clin, 30, pp. 301 - ix, http://dx.doi.org/10.1016/j.det.2011.11.008

Chatterjee S; Frew J; Mott J; McCallum H; Stevenson P; Maxwell R; Wilsdon J; Kelly CG, 2012, 'Variation in Radiotherapy Target Volume Definition, Dose to Organs at Risk and Clinical Target Volumes using Anatomic (Computed Tomography) versus Combined Anatomic and Molecular Imaging (Positron Emission Tomography/Computed Tomography): Intensity-modulated Radiotherapy Delivered using a Tomotherapy Hi Art Machine: Final Results of the VortigERN Study', Clinical Oncology, 24, pp. e173 - e179, http://dx.doi.org/10.1016/j.clon.2012.09.004

Frew J; Lim SW; Klausseger A; Chow CW; Tran K; Su J; Orchard D; Varigos G; Sawamura D; Nishie W; Shimizu H; Murrell DF, 2011, 'Autosomal dominant bullous dermolysis of the newborn associated with a heterozygous missense mutation p.G1673R in type VII collagen.', Australas J Dermatol, 52, pp. e1 - e4, http://dx.doi.org/10.1111/j.1440-0960.2010.00684.x

Frew JW; Murrell DF, 2011, 'Corticosteroid use in autoimmune blistering diseases.', Dermatol Clin, 29, pp. 535 - 544, http://dx.doi.org/10.1016/j.det.2011.06.004

Frew JW; Murrell DF, 2011, 'Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).', Dermatol Clin, 29, pp. 607 - 612, http://dx.doi.org/10.1016/j.det.2011.06.016

Frew JW; Martin LK; Murrell DF, 2011, 'Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus.', Dermatol Clin, 29, pp. 599 - 606, http://dx.doi.org/10.1016/j.det.2011.07.001

Frew JW; Murrell DF, 2011, 'Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis.', Dermatol Clin, 29, pp. 419 - viii, http://dx.doi.org/10.1016/j.det.2011.03.018

Gill SS; Frew J; Fry A; Adam J; Paleri V; Dobrowsky W; Chatterjee S; Kelly CG, 2011, 'Priorities for the Head and Neck Cancer Patient, their Companion and Members of the Multidisciplinary Team and Decision Regret', Clinical Oncology, 23, pp. 518 - 524, http://dx.doi.org/10.1016/j.clon.2011.03.014

Frew JW; Dopping-Hepenstal PJH; McGrath JA, 2010, 'Categorizing immunoflourescence mapping in epidermolysis bullosa with pyloric atresia: Use as a broad prognostic indicator', Australasian Journal of Dermatology, 51, pp. 212 - 214, http://dx.doi.org/10.1111/j.1440-0960.2010.00666.x

Venugopal SS; Yan H; Frew JW; Tran K; Melbourne W; Nelson J; Sturm M; Fogarty F; Marinkovich P; Igawa S; Ishida-Yamamoto A; Murrell DF, 2010, 'TRIAL OF FIBROBLAST CELL THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA', WOUND REPAIR AND REGENERATION, 18, pp. A74 - A74, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000279454700063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Frew JW; Martin LK; Nijsten T; Murrell DF, 2010, 'Erratum: Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument (British Journal of Dermatology (2009) 161 (1323-1330))', British Journal of Dermatology, 162, pp. 701, http://dx.doi.org/10.1111/j.1365-2133.2010.09642.x

Purdie KJ; Pourreyron C; Fassihi H; Cepeda-Valdes R; Frew JW; Volz A; Weissenborn SJ; Pfister H; Proby CM; Bruckner-Tuderman L; Murrell DF; Salas-Alanis JC; McGrath JA; Leigh IM; Harwood CA; South AP, 2010, 'No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma', Journal of Investigative Dermatology, 130, pp. 2853 - 2855, http://dx.doi.org/10.1038/jid.2010.243

Frew JW; Murrell DF, 2010, 'Quality of Life Measurements in Epidermolysis Bullosa: Tools for Clinical Research and Patient Care', Dermatologic Clinics, 28, pp. 185 - 190, http://dx.doi.org/10.1016/j.det.2009.10.019

Frew JW; Martin LK; Nijsten T; Murrell DF, 2009, 'Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument', British Journal of Dermatology, 161, pp. 1323 - 1330, http://dx.doi.org/10.1111/j.1365-2133.2009.09347.x

Frew JW, 2009, 'Performing surgery with a single electron: Electrosurgery and quantum mechanics', ANZ Journal of Surgery, 79, pp. 680 - 682, http://dx.doi.org/10.1111/j.1445-2197.2009.05051.x

Nading MA; Lahmar JJ; Frew JW; Ghionis N; Hanley M; Welch AK; Murrell DF, 2009, 'A ski and adventure camp for young patients with severe forms of epidermolysis bullosa.', J Am Acad Dermatol, 61, pp. 508 - 511, http://dx.doi.org/10.1016/j.jaad.2008.12.004

Frew J; Martin L; Murrell DF, 2008, 'Development of a quality of life measure specific for epidermolysis bullosa', Journal of Investigative Dermatology, 128, pp. S80 - S80

Frew J; Martin L; Murrell DF, 2008, 'Quality of life evaluation in epidermolysis bullosa', Journal of the American Academy of Dermatology, 58, pp. AB81 - AB81

Frew J; Martin L; Murrell DF, 2008, 'Quality of life evaluation in epidermolysis bullosa: Development of the QOLEB questionnaire', Journal of Investigative Dermatology, 128, pp. 1607 - 1607

Frew J; Mallick U; Perros P, 2007, 'A Patient with Asymmetric Parotid Uptake on a Diagnostic Iodine-131 Scan during Thyroid Cancer Follow-Up', Thyroid, 17, pp. 801 - 802, http://dx.doi.org/10.1089/thy.2006.0309

Henderson NC; Pollock KJ; Frew J; Mackinnon AC; Flavell RA; Davis RJ; Sethi T; Simpson KJ, 2007, 'Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure', Gut, 56, pp. 982, http://dx.doi.org/10.1136/gut.2006.104372

Frew J; Mort F, 1907, 'SOUTHERN HIGHLANDS FROM GLASGOW', SCOTTISH GEOGRAPHICAL MAGAZINE, 23, pp. 367 - 372, http://dx.doi.org/10.1080/00369220708733767

Frew J; Mort F, 1906, 'THE SOUTHERN HIGHLANDS FROM DUMGOYN', SCOTTISH GEOGRAPHICAL MAGAZINE, 22, pp. 322 - 324, http://dx.doi.org/10.1080/14702540608554666

Mort F; Frew J, 1906, 'THE SOUTHERN HIGHLANDS FROM GOUROCK', SCOTTISH GEOGRAPHICAL MAGAZINE, 22, pp. 435 - 438, http://dx.doi.org/10.1080/00369220608733658

Conference Papers

Islam R; Frew J; Kok C; Gupta M, 2026, 'New-Onset Vitiligo and Change in Disease Status Following COVID-19 Vaccination and COVID-19 Infection—An Online Survey', in Australasian Journal of Dermatology, pp. 109 - 113, http://dx.doi.org/10.1111/ajd.70027

Tzellos T; Sayed CJ; Gottlieb AB; Becherel P-A; Kirby B; Asai J; Frew JW; Pansar I; Tilt N; Rolleri R; Porter ML, 2025, 'Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT', in JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY-ELSEVIER, FL, Orlando, pp. AB137 - AB137, presented at Annual Meeting of the American-Academy-of-Dermatology (AAD), FL, Orlando, 07 March 2025 - 11 March 2025

Orenstein LAV; Shi VY; Lev-Tov H; Prens E; Ingram JR; Frew JW; Fujita H; Rolleri R; Lambert J; Crater C; Bechara FG; Davis L; Szepietowski JC, 2025, '2-year Impact of Bimekizumab on HSSQ Skin Pain in moderate to severe HS: Data from BE HEARD EXT', in JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, WILEY, pp. 133 - 133

Orenstein LA; Shi VY; Lev-Tov H; Prens E; Ingram JR; Frew JW; Fujita H; Rolleri R; Lambert J; Crater C; Bechara FG; Davis L; Szepietowski JC, 2025, '2-year impact of bimekizumab on HSSQ skin pain in moderate to severe HS: data from BE HEARD EXT', in JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, WILEY

Sayed CJ; Kirby B; Frew JW; Porter ML; Ingram JR; Prens E; Charrow AP; Gooderham MJ; Savage L; Reich K; Bechara FG, 2025, 'IHS4-100 responses and other IHS4 outcomes with the IL-17A-and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial', in JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY-ELSEVIER, pp. AB221 - AB221

Frew J; Flora A; Pham J; Woods J; Radzieta M; Dickson H; Malone M, 2025, 'The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial', in JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY-ELSEVIER, pp. AB313 - AB313

van der Zee HH; Kirby B; Bechara FG; Jemec GBE; Frew JW; Rolleri R; Joshi P; Pansar I; Tilt N; Sayed CJ, 2024, 'Bimekizumab impact on lesion count by anatomical region in moderate to severe hidradenitis suppurativa: Results to week 48 from BE HEARD I & II', in EXPERIMENTAL DERMATOLOGY, WILEY, FRANCE, Lyon, presented at 13th European Hidradenitis Suppurativa Conference (EHSF), FRANCE, Lyon, 07 February 2024 - 09 February 2024

Zouboulis CC; Kirby JS; Tzellos T; Khattri S; Alavi A; Podda M; del Marmol V; Spelman L; Rolleri R; Joshi P; Davis L; Pansar I; Frew JW, 2024, 'IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: Pooled results from the BE HEARD I & II phase 3 trials', in EXPERIMENTAL DERMATOLOGY, WILEY, FRANCE, Lyon, presented at 13th European Hidradenitis Suppurativa Conference (EHSF), FRANCE, Lyon, 07 February 2024 - 09 February 2024

Kirby B; Frew JW; Porter MJ; Bechara FG; Ingram JR; Prens EP; Charrow AP; Sayed CJ; Brennan N; Godwood A; Attar N; Cullen E; Reich K, 2024, 'The IL-17A-and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 12 International Hidradenitis Suppurativa Severity Score System (IHS4) results from the phase 2 MIRA trial', in EXPERIMENTAL DERMATOLOGY, WILEY, FRANCE, Lyon, presented at 13th European Hidradenitis Suppurativa Conference (EHSF), FRANCE, Lyon, 07 February 2024 - 09 February 2024


Back to profile page